Jane Street’s MoonLake Immunotherapeutics MLTX Stock Holding History

Jane Street’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.46M	Sell	453,625 -1,228,523	-73%	-$20.3M	﹤0.01%	2751
2025 Q4	$22.2M	Buy	1,682,148 +1,660,170	+7,554%	+$19.6M	﹤0.01%	1532
2025 Q3	$158K	Buy	+21,978	New	+$1.15M	﹤0.01%	9850
2025 Q2	–	Sell	-27,489	Closed	-$1.12M	–	10406
2025 Q1	$1.07M	Buy	27,489 +23,771	+639%	+$1.02M	﹤0.01%	5437
2024 Q4	$201K	Sell	3,718 -4,210	-53%	-$215K	﹤0.01%	8406
2024 Q3	$400K	Sell	7,928 -24,296	-75%	-$1.14M	﹤0.01%	7562
2024 Q2	$1.42M	Sell	32,224 -57,945	-64%	-$2.45M	﹤0.01%	5110
2024 Q1	$4.53M	Buy	90,169 +12,220	+16%	+$663K	﹤0.01%	2761
2023 Q4	$4.71M	Buy	77,949 +72,958	+1,462%	+$3.76M	﹤0.01%	2941
2023 Q3	$284K	Buy	+4,991	New	+$276K	﹤0.01%	7134
2023 Q2	–	Sell	-26,034	Closed	-$557K	–	9234
2023 Q1	$557K	Buy	+26,034	New	+$438K	﹤0.01%	6149
2022 Q2	–	Sell	-65,437	Closed	-$726K	–	10418
2022 Q1	$726K	Buy	+65,437	New	+$651K	﹤0.01%	6777

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street's MLTX Position: Q1 2026 in Review

Jane Street reduced its MoonLake Immunotherapeutics (MLTX) stake by 73% in Q1 2026, selling an estimated $20.3M and leaving 453,625 shares worth $8.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2751.

Jane Street first reported a position in MLTX in Q1 2022 and has held it in 12 quarters since. The position peaked at $22.2M in Q4 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Jane Street held 453,625 shares of MoonLake Immunotherapeutics worth $8.46M as of Q1 2026.
Jane Street sold 1,228,523 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $20.3M.
MoonLake Immunotherapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #2751 holding.
Jane Street first reported a position in MoonLake Immunotherapeutics in Q1 2022 and has held it in 12 quarters since.
Jane Street's MoonLake Immunotherapeutics position peaked at $22.2M in Q4 2025.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.